Corbus Takes On New Cystic Fibrosis Endpoint With Lenabasum

The US FDA has agreed to Corbus' plan to use pulmonary exacerbations as the only primary endpoint in a new large Phase II study, which is powered to serve as a registrational study.

Cystic fibrosis word cloud

The US FDA has given its blessing to Corbus Pharmaceuticals Holdings Inc. to use pulmonary exacerbations as the sole primary endpoint for a potentially registrational study of lenabasum in cystic fibrosis, a development that could help the product get to market much more quickly than if a forced expiration volume measure were used, according to CEO Yuval Cohen.

Lenabasum (formerly called anabasum) is a synthetic, oral small molecule that preferentially binds to the cannabinoid receptor 2 (CB2) expressed...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Rare Diseases

More from Pink Sheet